Literature DB >> 21144499

Can low-frequency repetitive transcranial magnetic stimulation really relieve medication-resistant auditory verbal hallucinations? Negative results from a large randomized controlled trial.

Christina W Slotema1, Jan Dirk Blom, Antoin D de Weijer, Kelly M Diederen, Rutger Goekoop, Jasper Looijestijn, Kirstin Daalman, Anne-Marije Rijkaart, René S Kahn, Hans W Hoek, Iris E C Sommer.   

Abstract

BACKGROUND: Several studies have applied low-frequency repetitive transcranial magnetic stimulation (rTMS) directed at the left temporoparietal area (TP) for the treatment of auditory verbal hallucinations (AVH), but findings on efficacy are inconsistent. Furthermore, recent functional magnetic resonance imaging (fMRI) studies indicate that the left TP is not a general focus of activation during the experience of AVH. The aims of this study are twofold: to investigate the effects of rTMS on AVH in a double blind, randomized, sham-controlled study; and to investigate whether the efficacy can be improved when rTMS is guided by individual fMRI scans of hallucinatory activation.
METHODS: Sixty-two patients with medication-resistant AVH were randomized over three conditions: rTMS targeted at the area of maximal hallucinatory activation calculated from individual fMRI scans during AVH, rTMS directed at the left TP, and sham treatment. Repetitive TMS was applied during 15 sessions of 20 min each, at 1 Hz and 90% of the individual motor threshold. The severity of AVH and other psychotic symptoms were monitored during treatment and 3-month follow-up, with the Auditory Hallucination Rating Scale, the Positive and Negative Syndrome Scale, and the Psychotic Symptom Rating Scales.
RESULTS: The effects of fMRI-guided rTMS and left TP rTMS on the severity of AVH were comparable to those of sham treatment. No differences in severity of general psychotic symptoms were found among the three treatment conditions.
CONCLUSIONS: Low-frequency rTMS administered to the left TP or to the site of maximal hallucinatory activation is not more effective for medication-resistant AVH than sham treatment.
Copyright © 2011 Society of Biological Psychiatry. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21144499     DOI: 10.1016/j.biopsych.2010.09.051

Source DB:  PubMed          Journal:  Biol Psychiatry        ISSN: 0006-3223            Impact factor:   13.382


  38 in total

1.  Taking back the brain: could neurofeedback training be effective for relieving distressing auditory verbal hallucinations in patients with schizophrenia?

Authors:  Simon McCarthy-Jones
Journal:  Schizophr Bull       Date:  2012-02-09       Impact factor: 9.306

2.  Repetitive transcranial magnetic stimulation as a treatment for auditory hallucinations.

Authors:  Iris E Sommer; Sebastian F W Neggers
Journal:  Neuropsychopharmacology       Date:  2014-01       Impact factor: 7.853

Review 3.  The treatment of hallucinations in schizophrenia spectrum disorders.

Authors:  Iris E C Sommer; Christina W Slotema; Zafiris J Daskalakis; Eske M Derks; Jan Dirk Blom; Mark van der Gaag
Journal:  Schizophr Bull       Date:  2012-02-24       Impact factor: 9.306

4.  fMRI capture of auditory hallucinations: Validation of the two-steps method.

Authors:  Arnaud Leroy; Jack R Foucher; Delphine Pins; Christine Delmaire; Pierre Thomas; Mathilde M Roser; Stéphanie Lefebvre; Ali Amad; Thomas Fovet; Nemat Jaafari; Renaud Jardri
Journal:  Hum Brain Mapp       Date:  2017-06-28       Impact factor: 5.038

5.  Repetitive transcranial magnetic stimulation (rTMS) in schizophrenia with treatment-refractory auditory hallucinations and major self-mutilation.

Authors:  Torsten Schulz; Christoph Berger; Beate Krecklow; Jens Kurth; Sarah Schwarzenboeck; Paul Foley; Johannes Thome; Bernd Joachim Krause; Jacqueline Hoeppner
Journal:  J Neural Transm (Vienna)       Date:  2014-01-08       Impact factor: 3.575

Review 6.  Efficacy of Transcranial Magnetic Stimulation (TMS) in the Treatment of Schizophrenia: A Review of the Literature to Date.

Authors:  Jonathan C Cole; Carolyn Green Bernacki; Amanda Helmer; Narsimha Pinninti; John P O'reardon
Journal:  Innov Clin Neurosci       Date:  2015 Jul-Aug

7.  Transcranial magnetic stimulation of Wernicke's and Right homologous sites to curtail "voices": a randomized trial.

Authors:  Ralph E Hoffman; Kun Wu; Brian Pittman; John D Cahill; Keith A Hawkins; Thomas Fernandez; Jonas Hannestad
Journal:  Biol Psychiatry       Date:  2013-02-26       Impact factor: 13.382

8.  Theta Burst Transcranial Magnetic Stimulation for Auditory Verbal Hallucinations: Negative Findings From a Double-Blind-Randomized Trial.

Authors:  Sanne Koops; Edwin van Dellen; Maya J L Schutte; Wendy Nieuwdorp; Sebastiaan F W Neggers; Iris E C Sommer
Journal:  Schizophr Bull       Date:  2015-07-28       Impact factor: 9.306

9.  The 3rd Schizophrenia International Research Society Conference, 14-18 April 2012, Florence, Italy: summaries of oral sessions.

Authors:  Brandon Abbs; Rashmin M Achalia; Adegoke O Adelufosi; Ahmet Yiğit Aktener; Natalie J Beveridge; Savita G Bhakta; Rachael K Blackman; Emre Bora; M S Byun; Maurice Cabanis; Ricardo Carrion; Christina A Castellani; Tze Jen Chow; M Dmitrzak-Weglarz; Charlotte Gayer-Anderson; Felipe V Gomes; Kristen Haut; Hiroaki Hori; Joshua T Kantrowitz; Taishiro Kishimoto; Frankie H F Lee; Ashleigh Lin; Lena Palaniyappan; Meina Quan; Maria D Rubio; Sonia Ruiz de Azúa; Saddichha Sahoo; Gregory P Strauss; Aleksandra Szczepankiewicz; Andrew D Thompson; Antonella Trotta; Laura M Tully; Hiroyuki Uchida; Eva Velthorst; Jared W Young; Anne O'Shea; Lynn E Delisi
Journal:  Schizophr Res       Date:  2012-08-19       Impact factor: 4.939

10.  Individualized rTMS neuronavigated according to regional brain metabolism ((18)FGD PET) has better treatment effects on auditory hallucinations than standard positioning of rTMS: a double-blind, sham-controlled study.

Authors:  Monika Klirova; Jiri Horacek; Tomas Novak; Jan Cermak; Filip Spaniel; Lucie Skrdlantova; Pavel Mohr; Cyril Höschl
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2012-09-15       Impact factor: 5.270

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.